The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy.
Crit Rev Oncol Hematol
; 72(1): 65-75, 2009 Oct.
Article
em En
| MEDLINE
| ID: mdl-19147371
ABSTRACT
Colorectal cancer (CRC) caused nearly 204,000 deaths in Europe in 2004. Despite recent advances in the treatment of advanced disease, which include the incorporation of two new cytotoxic agents irinotecan and oxaliplatin into first-line regimens, the concept of planned sequential therapy involving three active agents during the course of a patient's treatment and the integrated use of targeted monoclonal antibodies, the 5-year survival rates for patients with advanced CRC remain unacceptably low. For patients with colorectal liver metastases, liver resection offers the only potential for cure. This review, based on the outcomes of a meeting of European experts (surgeons and medical oncologists), considers the current treatment strategies available to patients with CRC liver metastases, the criteria for the selection of those patients most likely to benefit and suggests where future progress may occur.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Hepatectomia
/
Neoplasias Hepáticas
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Crit Rev Oncol Hematol
Ano de publicação:
2009
Tipo de documento:
Article